Health & Environmental Research Online (HERO)


Print Feedback Export to File
7087403 
Journal Article 
Recent research progress on natural small molecule bibenzyls and its derivatives in Dendrobium species 
He, Li; Shi, J; Huang, S; Guo, Li; Su, Q; Bai, Lan; Li, M; Liu, J; Liu, X; Zhang, C; Jiang, Z; He, Jun; , 
2020 
Yes 
European Journal of Medicinal Chemistry
ISSN: 0223-5234
EISSN: 1768-3254 
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER 
ISSY-LES-MOULINEAUX 
Orchidaceous plant Dendrobium genus is often used as a tonic, and its phenolic components have attracted attention for its anti-tumor and anti-diabetic complications. Bibenzyls is one of the essential phenolic active ingredients in the Dendrobium genus. At present, 89 bibenzyl derivatives have been extracted and identified from 46 Dendrobium species. The activity studies have shown that 42 compounds have pharmaceutical activity. Among them, 23 compounds showed antitumor activity; 7 compounds showed anti-diabetes and its complications activity; 10 compounds exhibited neuroprotective effects; 18 compounds showed antioxidant effects; 11 compounds had anti-inflammatory activity; 3 compounds had Antiplatelet aggregation effects; 3 compounds had antibacterial and antiviral effects. The Bibenzyls is small-molecular compounds of natural origin and widely sourced. Previous studies showed that the bibenzyls has good anti-tumor, anti-diabetes and its complications, and neuroprotective effects, and it has great potential for treating tumors, diabetes and its complications, Alzheimer's disease (AD) and Parkinson's disease (PD). Additionally, compounds such as moscatilin (1), gigantol (2) and chrysotoxine (3) have been further studied as lead compounds, and compounds exhibited therapeutical effects had been synthesized. Enough pieces of evidences have shown that the Bibenzyls have good development prospects. This article reviews the pharmacological effects of bibenzyls in Dendrobium species and provides an idea for its further development. (C) 2020 Elsevier Masson SAS. All rights reserved.